Target intelligence / Profile preview

DNA polymerase subunit gamma, catalytic subunit (POLG)

Target
POLG
Molecular classification
Enzyme, DNA polymerase (type-A family), 3'-5' exonuclease, 5'-deoxyribose-phosphate lyase, Mitochondrial protein
01

Overview

DNA polymerase subunit gamma, catalytic subunit (POLG), is the primary enzyme responsible for replicating and repairing mitochondrial DNA in human cells. This large mitochondrial enzyme functions as the catalytic α (alpha) subunit of the heterotrimeric DNA polymerase gamma holoenzyme, which also includes a dimeric accessory β (beta) subunit that increases processivity and DNA binding. POLG exhibits polymerase activity for DNA synthesis, 3'-5' exonuclease activity for proofreading, and 5'-deoxyribose-phosphate lyase activity for base excision repair. Mutations in POLG are associated with a spectrum of mitochondrial diseases characterized by impaired energy metabolism, neurodegeneration, hepatopathy, and myopathy. Off-target inhibition or mutation of POLG can cause or exacerbate mitochondrial toxicities, especially in the context of certain drugs such as valproic acid or some nucleoside analogs, making POLG both a clinically significant disease gene and an important safety consideration in drug development.

Other names
DNA polymerase gamma catalytic subunitDNA polymerase gamma-1POLG1POLGAMDP13'-5' exodeoxyribonuclease5'-deoxyribose-phosphate lyasemitochondrial DNA polymerase catalytic subunitPolG-alphaMIRASMTDPS4AMTDPS4BPEOSANDOSCAEDNA polymerase subunit gamma-1
02

Mechanism of action

Inhibition (by off-target drug effects leading to mitochondrial dysfunction); Mutation rescue (small molecules restoring mutant POLG function)

03

Biological functions

Mitochondrial DNA replicationMitochondrial DNA repairProofreading of mitochondrial DNABase excision repair
04

Disease associations

Mitochondrial disorders (progressive external ophthalmoplegia, Alpers-Huttenlocher syndrome, SANDO, MNGIE)Neurodegenerative diseaseHepatic failure
05

Safety considerations

Drug-induced mitochondrial toxicity, especially with valproic acid and some antivirals in patients with POLG mutationsFatal liver failure risk in children with POLG mutations taking valproic acid
06

Interacting drugs

Valproic acid (induces toxicity in POLG-deficient patients)

2 more in the full profile.

07

Biomarkers

POLG genetic mutation status (for disease risk and drug toxicity prediction)Mitochondrial DNA depletion or mutation load (for disease monitoring)

Beyond the preview

Go deeper on DNA polymerase subunit gamma, catalytic subunit (POLG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase subunit gamma, catalytic subunit (POLG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call